Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Alpha Tau Medical Ltd ( (DRTS) ) just unveiled an update.
On February 3, 2025, Alpha Tau Medical Ltd. announced that the FDA has approved an IDE supplement to expand their clinical trial of Alpha DaRT® in treating pancreatic cancer. This approval allows the trial to include 30 patients across two cohorts with either locally advanced or metastatic disease at up to 10 U.S. sites, reflecting a significant step forward in exploring new treatments for pancreatic cancer.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company specializing in the research, development, and potential commercialization of Alpha DaRT® technology for treating solid tumors. Founded in 2016, the company focuses on utilizing innovative alpha-radiation therapy to target tumors while sparing healthy tissue.
YTD Price Performance: 19.35%
Average Trading Volume: 80,788
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $258.7M
Find detailed analytics on DRTS stock on TipRanks’ Stock Analysis page.
